Correction Cite This: ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX
pubs.acs.org/acsmedchemlett
Correction to “Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD)” Bharat Lagu,* Arthur F. Kluge, Effie Tozzo, Ross Fredenburg, Eric L. Bell, Matthew M. Goddeeris, Peter Dwyer, Andrew Basinski, Ramesh S. Senaiar, Mahaboobi Jaleel, Nirbhay Kumar Tiwari, Sunil K. Panigrahi, Narasimha Rao Krishnamurthy, Taisuke Takahashi, and Michael A. Patane ACS Med. Chem. Lett. 2018, 9, 935−940. DOI:10.1021/acsmedchemlett.8b00287
ACS Med. Chem. Lett. Downloaded from pubs.acs.org by 46.148.124.25 on 04/26/19. For personal use only.
W
e would like to add the following publications to the list of references for this article that reported selective PPARdelta modulators for potential treatment of Duchenne Muscular Dystrophy (DMD).
■
REFERENCES
(1) Miura, P.; Chakkalakal, J. V.; Boudreault, L.; Bélanger, G.; Hébert, R. L.; Renaud, J.-M.; Jasmin, B. J. Pharmacological activation of PPARβ/δ stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice. Hum. Mol. Genet. 2009, 18 (23), 4640−4649. (2) Ljubicic, V.; Burt, M.; Jasmin, B. J. The therapeutic potential of skeletal muscle plasticity in Duchenne muscular dystrophy: phenotypic modifiers as pharmacologic targets. FASEB J. 2014, 28 (2), 548−568.
© XXXX American Chemical Society
A
DOI: 10.1021/acsmedchemlett.9b00160 ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX
